Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 2/20 | 0.52 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 5/20 | 0.44 |
| ▸ | DHFR | P00374 | 3/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.39 |
| ▸ | USP7 | Q93009 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2884889 | 0.86 | ROCK1 (0.56) | ROCK1MAPKAPK2TRPA1USP7MIF | |
| SCHEMBL2068939 | 0.81 | MAPKAPK2 (0.65) | ROCK1MAPKAPK2TRPA1DHFRUSP7 | |
| SCHEMBL2876364 | 0.79 | ROCK1 (0.58) | ROCK1TRPA1MAOB | |
| SCHEMBL2882175 | 0.77 | ROCK1 (0.50) | ROCK1TRPA1 | |
| SCHEMBL5043115 | 0.76 | ROCK1 (0.52) | ROCK1TRPA1 | |
| SCHEMBL8320486 | 0.74 | ROCK1 (0.71) | ROCK1MAPKAPK2 | |
| SCHEMBL1388354 | 0.74 | DHFR (0.68) | DHFR | |
| SCHEMBL2745386 | 0.74 | DHFR (0.59) | MAPKAPK2DHFRUSP7 | |
| Hydrochloric Acid SCHEMBL4478858 | 0.72 | DHFR (0.57) | MAPKAPK2DHFRUSP7 | |
| Hydrochloric Acid SCHEMBL29430410 | 0.72 | DHFR (0.57) | MAPKAPK2DHFRUSP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737153-B2 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-15 | — | — | US | disclosed |
| US-20060241127-A1 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | BAYER HEALTHCARE AG (DE) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241127-A1 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | ROCK1, ROCK2, RHOA | ROCK1 1/4885MAPKAPK2 40/4885TRPA1 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.